Anqi Li

864 total citations
23 papers, 685 citations indexed

About

Anqi Li is a scholar working on Cancer Research, Molecular Biology and Oncology. According to data from OpenAlex, Anqi Li has authored 23 papers receiving a total of 685 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Cancer Research, 13 papers in Molecular Biology and 3 papers in Oncology. Recurrent topics in Anqi Li's work include Cancer, Hypoxia, and Metabolism (6 papers), MicroRNA in disease regulation (5 papers) and Cancer-related molecular mechanisms research (5 papers). Anqi Li is often cited by papers focused on Cancer, Hypoxia, and Metabolism (6 papers), MicroRNA in disease regulation (5 papers) and Cancer-related molecular mechanisms research (5 papers). Anqi Li collaborates with scholars based in China, United States and Australia. Anqi Li's co-authors include Ying� Qin, Yunlong Bai, Xi Sun, Yueqiu Wang, Jie Lv, Fan Yang, Hui Che, Lihong Wang, Yanan Jiang and Er Yue and has published in prestigious journals such as Journal of Clinical Investigation, The Journal of Immunology and The Science of The Total Environment.

In The Last Decade

Anqi Li

18 papers receiving 679 citations

Peers

Anqi Li
Comparison fields: 5 of 83
  • Molecular Biology 472
  • Cancer Research 296
  • Cardiology and Cardiovascular Medicine 111
  • Immunology 94
  • Nephrology 73
Replace Hans‐Joerg Hippe with:
Hans‐Joerg Hippe Germany
Piera Trionfini Italy
Mengsi Hu China
Muhammad Tarek Abdel Ghafar Egypt
Zhaoya Liu China
Hongyan Li China
Mingqi Tan China
Shasha Lv China
Yunchang Yuan China
Hans‐Joerg Hippe Germany View profile →
Citations per field, relative to Anqi Li
Anqi Li · 1×
Citations per year, relative to Anqi Li
Anqi Li · 1×

Countries citing papers authored by Anqi Li

Since Specialization
Citations

This map shows the geographic impact of Anqi Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anqi Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anqi Li more than expected).

Fields of papers citing papers by Anqi Li

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anqi Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anqi Li. The network helps show where Anqi Li may publish in the future.

Co-authorship network of co-authors of Anqi Li

This figure shows the co-authorship network connecting the top 25 collaborators of Anqi Li. A scholar is included among the top collaborators of Anqi Li based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anqi Li. Anqi Li is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
# Work Indexed citations
1 0
2 0
3 0
4 1
5 0
6 11
7 13
8 1
9 24
10 8
11 14
12 12
13 13
14 15
15 144
16 42
17 225
18 31
19 84
20
Recombinant human endostatin combined with navelbine and cisplatin in first line treatment of advanced non-small cell lung cancer
1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026